News Releases - Ascendis Pharma
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024. November 4, 2024. Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases. September 30, 2024.
Ascendis Pharma Presents New Data and Updated Results from …
As of the April 16, 2024 data cutoff, confirmed clinical responses were observed in 40% (two out of five) of efficacy-evaluable patients from Cohort 4, suggesting potential synergy of Ascendis ...
Ascendis Pharma Reports Full Year 2022 Results
Nov 18, 2021 · For the full year 2022, Ascendis Pharma reported a net loss of €583.2 million, or €10.40 per share (basic and diluted) compared to a net loss of €383.6 million, or €7.00 per share (basic and diluted) for the same period in 2021.
Ascendis Pharma to Report Third Quarter 2024 Financial Results …
Nov 18, 2021 · COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss ...
Ascendis Pharma to Report Third Quarter 2024 Financial Results …
6 days ago · --Ascendis Pharma A/S today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets.
Ascendis Pharma Expands Capital to Fuel Growth - Markets Insider
1 day ago · Ascendis Pharma has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with a current share capital of DKK 60,642,144.
Novo pens $285M biobucks deal to use Ascendis' tech to create …
Nov 4, 2024 · Novo Nordisk Ascendis Pharma GLP-1 Licensing deals. Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer ...
After 2 delays over 15 months, FDA approves Ascendis' Yorvipath
Aug 12, 2024 · After two delays, the FDA has signed off on Ascendis' Yorvipath, which is the first approved product for hypoparathyroidism in adults in the US.
Ascendis Pharma and Novo Nordisk Join Forces - Yahoo Finance
Nov 4, 2024 · Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and ...
Ascendis Pharma Announces Submission of Supplemental …
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA ® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone ...
- Some results have been removed